Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-lactamases are bacterial enzymes classified into molecular classes (A, C, and D) based on amino acid sequence and function; all use a serine residue at their active site to hydrolyze beta-lactam antibiotics, conferring resistance to penicillins, cephalosporins, carbapenems, and monobactams depending on type. Class A enzymes include common ESBLs (TEM, SHV, CTX-M, KPC), class C enzymes are largely cephalosporinases (AmpC-type), and class D includes diverse OXA-type enzymes. These enzymes represent a major mechanism of acquired and intrinsic antibiotic resistance among clinically significant bacteria; inhibitors such as clavulanic acid, tazobactam, and avibactam are used to restore antibiotic activity against some enzyme types, although resistance continues to evolve, presenting major challenges in infectious disease therapy and patient safety.
Beta-lactam antibiotics: bind and are hydrolyzed/inactivated unless the enzyme is inhibited or overcome. Beta-lactamase inhibitors: bind and inhibit the enzyme, restoring antibiotic efficacy.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactamase (class A, class C, and class D variants).